Nektar Therapeutics (NKTR)
39.84
-1.34
(-3.24%)
USD |
NASDAQ |
Oct 12, 16:00
39.84
0.00 (0.00%)
After-Hours: 20:00
Nektar Therapeutics Free Cash Flow (Quarterly) : -75.86M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -75.86M |
| March 31, 2026 | -44.32M |
| December 31, 2025 | -64.98M |
| September 30, 2025 | -48.88M |
| June 30, 2025 | -45.78M |
| March 31, 2025 | -49.06M |
| December 31, 2024 | -46.65M |
| September 30, 2024 | -44.60M |
| June 30, 2024 | -37.89M |
| March 31, 2024 | -48.04M |
| December 31, 2023 | -47.28M |
| September 30, 2023 | -42.15M |
| June 30, 2023 | -51.68M |
| March 31, 2023 | -52.35M |
| December 31, 2022 | -58.22M |
| September 30, 2022 | -83.07M |
| June 30, 2022 | -75.77M |
| March 31, 2022 | -92.63M |
| December 31, 2021 | -157.43M |
| September 30, 2021 | -104.07M |
| June 30, 2021 | -86.18M |
| March 31, 2021 | -79.96M |
| December 31, 2020 | -100.39M |
| September 30, 2020 | -54.58M |
| June 30, 2020 | -86.60M |
| Date | Value |
|---|---|
| March 31, 2020 | -78.98M |
| December 31, 2019 | -128.89M |
| September 30, 2019 | -73.96M |
| June 30, 2019 | -65.56M |
| March 31, 2019 | -86.54M |
| December 31, 2018 | -126.24M |
| September 30, 2018 | -73.23M |
| June 30, 2018 | 956.90M |
| March 31, 2018 | -53.45M |
| December 31, 2017 | -82.79M |
| September 30, 2017 | 92.14M |
| June 30, 2017 | -60.78M |
| March 31, 2017 | -38.66M |
| December 31, 2016 | -55.06M |
| September 30, 2016 | -27.87M |
| June 30, 2016 | -15.16M |
| March 31, 2016 | -25.33M |
| December 31, 2015 | -77.58M |
| September 30, 2015 | -18.17M |
| June 30, 2015 | -50.78M |
| March 31, 2015 | 62.25M |
| December 31, 2014 | -28.51M |
| September 30, 2014 | -46.90M |
| June 30, 2014 | -9.753M |
| March 31, 2014 | -66.81M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Eli Lilly & Co. | 4.475B |
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Tonix Pharmaceuticals Holding Corp. | -42.44M |
| Capricor Therapeutics, Inc. | -37.39M |
| Kyntra Bio, Inc. | -3.991M |